Bayer, J&J clot drug seen winning U.S. panel nod

WASHINGTON/NEW YORK (Reuters) - An experimental stroke preventer from Bayer and Johnson & Johnson is likely to win a recommendation from U.S. health advisers next week, but not without concern over risks seen when patients come off the drug.

. Read More

Free Web Hosting